TRVI Trevi Therapeutics, Inc.: institutional ownership and insider trading
226 funds reported holding $2.89B of Trevi Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $244M, with 37 new positions and 19 funds selling out; over the last 12 months insiders bought $0 and sold $596K on the open market.
Famous investors holding TRVI
- Andreas Halvorsen (Viking Global Investors): $28.8M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $5.26M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $3.01M, 0.0% of the portfolio
Largest institutional holders of TRVI
- NEA Management Company, LLC — $247M
- FMR LLC — $234M
- BlackRock, Inc. (BLK) — $208M
- Frazier Life Sciences Management, L.P. — $185M
- WELLINGTON MANAGEMENT GROUP LLP — $106M
- VANGUARD CAPITAL MANAGEMENT LLC — $103M
- Vivo Capital, LLC — $95.0M
- VANGUARD GROUP INC — $80.6M
- Woodline Partners LP — $76.1M
- Vestal Point Capital, LP — $57.8M
Recent TRVI insider trades
- Sep 15, 2026: Heffernan Michael Thomas sold 39,473 shares ($596K)
- Mar 25, 2025: Sciascia Thomas sold 2,631 shares ($17.4K)
- Mar 21, 2025: Good Jennifer L sold 5,263 shares ($34.6K)
- Mar 10, 2025: Simon Farrell sold 81,313 shares ($549K)
5%+ owners
- New Enterprise Associates 16, L.P.: 10.5% (Schedule 13D/A, filed May 7, 2026)
- FMR LLC: 8.8% (Schedule 13G/A, filed Aug 6, 2026)